Education
About Us
Working with TipRanks
Follow Us
Sight Sciences (SGHT)
NASDAQ:SGHT
SGHT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.03 - $8.45
Previous CloseN/A
Volume59.09K
Average Volume (3M)144.71K
Market Cap
$184.58M
Enterprise Value$63.92M
Total Cash (Recent Filing)$108.77M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 07, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding51,702,087
10 Day Avg. Volume105,896
30 Day Avg. Volume144,708
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio-7.31
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit0.96
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$3.72Price Target Upside-1.59% Downside
Rating ConsensusHold
Number of Analyst Covering7
Sight Sciences News
PremiumCompany Announcements
Sight Sciences Holds Annual Stockholders Meeting
PremiumCompany Announcements
Sight Sciences, Inc. Earnings Call: Mixed Results and Strategic Focus
Bulls Say, Bears Say
Bulls Say
Financial StabilitySight maintains a solid $120 million cash position, enabling flexibility for ongoing product launches, market access efforts, and further R&D investments.
Product PerformanceTearCare is preferred for its superior patient comfort and long-lasting benefits, indicating high patient satisfaction and clinical effectiveness.
Revenue PerformanceSGHT's first-quarter sales of $17.5 million were $1 million above estimates, showcasing better-than-expected performance.
Bears Say
Market AccessWhile market access remains a challenge, TearCare's potential to disrupt the dry eye market is contingent on receiving reimbursement coverage.
Sales GuidanceManagement reiterated full-year sales guidance of a 6% to 12% decline year-over-year, indicating ongoing challenges.
Tariffs ImpactTariffs are expected to be a ~$4M headwind, with management beginning to transition manufacturing outside of China.
Ownership Overview
34.68% Insiders
5.51% Mutual Funds
8.69% Other Institutional Investors
44.18% Public Companies and
Individual Investors
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $2.03 and its highest was $8.45 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $184.58M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Aug 07, 2025 which is in 13 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on May 08, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.283 by $0.003.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Overvalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.26.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 51,702,087 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.283. Following the earnings report the stock price went up 1.65%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
Sight Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.72 (-1.59% Downside)
$3.72 (-1.59% Downside)
Hedge Fund Trend
Decreased
By 11.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $904.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-55.26%
12-Months-Change
Fundamentals
Return on Equity
-52.87%
Trailing 12-Months
Asset Growth
-16.64%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences (SGHT) is a medical technology company focused on developing and commercializing innovative solutions to transform care in ophthalmology and optometry. The company operates primarily in the healthcare sector, offering products designed to address prevalent eye diseases such as glaucoma and dry eye disease. Sight Sciences aims to improve patient outcomes through its advanced medical devices and cutting-edge technology.
SGHT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with solid performance in the surgical glaucoma segment and positive reception of new product launches, but faced challenges with revenue declines, tariff costs, and the lack of reimbursement for TearCare. The company's strategic initiatives and cost management are showing progress, yet external market conditions and reimbursement hurdles remain significant concerns.Read More>SGHT Stock 12 Month Forecast
Average Price Target
$3.72
▼(-1.59%Downside)